Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...

CSL shares have fallen almost 40% in 2025. Investors are now asking if the worst is already behind the stock. CSL shares fell nearly 40% in 2025 due to underwhelming profit guidance, elevated costs, ...

Should you be buying the dip? Let's find out. CSL shares crashed 39% during 2025 to $172.65 as management slashed revenue and profit growth guidance, signalling that the biotherapeutics giant's next ...

CSL has said that with flu jab rates in the US down between 12% and 14% this year, it has decided to delay the planned spinout of its Seqirus vaccines business and cut its profit forecast for the ...

The CSL Ltd (ASX: CSL) share price has tested investor patience like few other blue chips in recent memory. After falling almost 40% during 2025, CSL shares are now trading around the $170 mark. That ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring ...